Orexo AB · OMXSTO:ORX
Orexo AB — Pareto Healthcare Conference 2021
25 slides from Orexo AB's conference presentation, Sep 1, 2021
Slide 1: Pareto Healthcare Conference Sep 1-2, 2021
Improving the lives of people suffering from mental illness and substance use disorders Pareto Healthcare Conference Sep 1-2, 2021 Nasdaq Stockholm: ORX US OTC Market: ORXOY (ADR)
Slide 2: Legal Disclaimer
Legal Disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Orex
Slide 3: Orexo – focusing on the large and growing space of treatment of mental illness
Orexo – focusing on the large and growing space of treatment of mental illness • Developed four commercial • Net revenues FY´20 SEK 623 million Profitable US Pharma pharmaceutical products • EBITDA FY´20 SEK 347 million operations with worldwide approval • EBIT Margin FY´20 53 percent • Commercial p
Slide 4: ZUBSOLV continues to be a strong cash contributor
ZUBSOLV® continues to be a strong cash contributor
Slide 5: Market volume reaching new highs in Q2 2021
Market volume reaching new highs in Q2 2021, with YoY growth rate decelerating due to drop in Q1 2021 Q2’21 vs Q2’20 Growth Market Volume Sales, quarterly NTRx Total Market: +8% 2 500 000 Open The growth is driven by the Public segment, 2 000 000 Non-reimbursed although Public growth is lower than r
Slide 6: ZUBSOLV overall volume stable supported by resilience in Open segment
ZUBSOLV® overall volume stable supported by resilience in Open segment UHC/Humana continue to decline, but the decline is decelerating ZUBSOLV® by Access Segments ZUBSOLV® change R4W Average NTRx in Bold Color; Single Week NTRx in Lighter Shade (Q2 2021 vs Q1 2021) Open (ex. Non-Retail) UHC/Humana N
Slide 7: Q221 - US Pharma Operating Margin (LTM) 55%
Q221 - US Pharma Operating Margin (LTM) 55% Sales and gross profit EBIT LTM, USD m LTM, USD m LTM, % 80 40,0 55% 70 45% 30,0 60 35% 20,0 25% 50 15% 40 10,0 5% 30 - -5% Q2 2019 Q2 2020 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q3 2019 Q4 2019 Q1 2020 Q3 2
Slide 8: ZUBSOLV growth drivers amid Covid-19 challenges
While ZUBSOLV® is facing multiple growth drivers, Covid-19 continues to create a challenging environment Comments to Q2 QoQ development ZUBSOLV® growth drivers • The development in ZUBSOLV´s core • Multiple comprehensive activities on-going on payer segment, the Commercial federal and state levels t
Slide 9: Opioid litigations and settlements increase resources to treat OUD
Opioid litigations and settlements creates significant increase in resources available to treat OUD and open up new opportunities 9
Slide 10: Expanding the commercialization model in DTx
Expanding the commercialization model in DTx TM
Slide 11: DTx - an attractive opportunity to diversify and drive future growth
DTx - an attractive opportunity to diversify the company and drive future growth • Continuous increase in scientific evidence of the value from digital health products • Covid-19 has significantly accelerated the utilization of non face to face interactions between healthcare providers and patients
Slide 12: Digital therapeutics is in its infancy - several hurdles remain
Digital therapeutics is in its infancy - while the potential is significant, several hurdles need to be addressed before the market takes off Commercialization Reimbursement • Optimal pathways to commercialize and scale DTx are • Many payors still to establish payment and still unchartered reimburse
Slide 13: Orexo Digital Therapeutics (DTx)
Orexo Digital Therapeutics (DTx) Twelve weeks of digital cognitive behavioral therapy for mild 17 million patients in the US to moderate to severe depression suffered from depression pre- One of the most studied digital therapies in depression with Covid 11+ original trials in over 2,800 patients Tw
Slide 14: Orexo portfolio has unparalleled clinical evidence in the DTx landscape
The Orexo portfolio has unparalleled clinical evidence and functionality in the DTx landscape DTx Landscape Only Orexo offers digital therapeutics with evidence from 11+ well-controlled clinical trials powered to evaluate efficacy. Our proprietary AI platform learns users’ preferences and is designe
Slide 15: modia randomized clinical trial initiated in 400 patients
modia™ randomized clinical trial initiated in 400 patients Outcome essential for differentiation enabling market access and appropriate regulatory FDA classification 400 participants at 35 sites across the US The randomized, open-label, parallel-group study will evaluate whether the use of modia™ in
Slide 16: Multiple commercial contracts signed with healthcare providers
Multiple commercial contracts signed with healthcare providers… ……of which one with a Integrated Health Distribution Network – Trinity Health North Dakota New Commercial agreements signed in Q2 • Trinity Health North Dakota • NYC clinic • Mental health hospital in St Louis • Start-up company providi
Slide 17: The Sober Grid partnership will reach 300 000 individuals
The Sober Grid partnership will reach 300 000 individuals struggling with mental health issues - Sober Grid is the largest global digital network for people trying to reach, or that are in, recovery from addiction - The partnership will evolve in three phases • Phase 1: deprexis® and vorvida® will b
Slide 18: OX124 - overdose rescue medication, approaching US launch in 2023
OX124 - overdose rescue medication, approaching US launch in 2023
Slide 19: OX124 - a new stronger overdose rescue medication with naloxone
OX124 - a new stronger overdose rescue medication with naloxone Expected launch in 2023 The unmet need In 2020, the number of drug-related overdose deaths reached more than 92,000 for the first time in history, an increase of 31%. 74% of these deaths were caused by opioids and within the opioid-rela
Slide 20: Good progress YTD with the aim to launch in the US in 2023
Good progress YTD with the aim to launch in the US in 2023 Progress January-July…. …..onwards Commercial supply chain established H2 Perform the pivotal bridging study 12 month stability study initiated H2- File the New Drug Application with the FDA 2022 Pivotal trial initiated 2023 Launch in
Slide 21: Financial information & legal update
Financial information & legal update
Slide 22: A transformative last 12 months period building for future growth
A transformative last 12 months period building for future growth Numbers reflects loss in Abstral® royalty due to patent expiration and investments in the build-up of DTx venture Group net revenues LTM Q2´21even LTM1,2 US Pharma net revenues LTM Q2´21even et revenues SEK 585 m SEK 539 m Group EBITD
Slide 23: No changes in the two ongoing legal processes in Q2
No changes in the two ongoing legal processes in Q2, except for two new patents issued for ZUBSOLV® Subpoena Patent infringement litigation against Sun Pharma • On July 14, 2020 Orexo US received subpoenas to • Orexo on September 13 filed a patent infringement provide US Authorities with certain inf
Slide 24: Summary - Strong value drivers for long-term growth
Summary - Strong value drivers for long-term growth Future Product portfolio Strong cash conversion to value addressing large and growing support growth drivers markets Leveraging our US Expanding pipeline Entering digital commercial excellence targeting unmet medical therapeutics, a new n
Slide 25: Thank You
Thank You IR Contact: Lena Wange, IR & Communications Director, [email protected]. For more information please visit www.orexo.com. You can also follow Orexo at Twitter @orexoabpubl, LinkedIn and YouTube